Eli Lilly's Famed Weight Loss Drug Zepbound Scores Chinese Approval
Eli Lilly's Famed Weight Loss Drug Zepbound Scores Chinese Approval
On Friday, China's National Medical Products Administration approved Eli Lilly And Co Tirzepatide for long-term weight management.
周五，中国国家医疗产品管理局批准礼来公司的开多巴肽用于长期体重管理。
It is suitable for long-term weight management of adults whose body mass index (BMI) meets the following requirements based on diet control and increased exercise: ≥28 kg/m2 (obese) or ≥24 kg/m2 (overweight) with at least one condition.
适用于长期减重管理的成年人，其身体质量指数（BMI）符合以下要求：通过饮食控制和增加运动达到≥28 kg / m2（肥胖）或≥24 kg / m2（超重）至少有一种病情控制。
Tirzepatide is known in the U.S. as Mounjaro for diabetes and Zepbound for weight loss.
Tirzepatide在美国被称为糖尿病药物Mounjaro和减肥药物Zepbound。
In May, the Chinese regulatory authority approved Tirzepatide in China to treat adults with type 2 diabetes.
今年五月，中国监管机构批准了Tirzepatide用于治疗2型糖尿病的成年人。
In March, Eli Lilly revealed that it has identified bacteria and elevated impurity levels in products falsely claiming to be compounded versions of tirzepatide, the active ingredient in its widely-used diabetes medication Mounjaro and the weight loss treatment Zepbound.
三月份，Eli Lilly公司披露了一些产品，声称是合成型Tirzepatide的产品中存在细菌和杂质含量升高的虚假情况，这是其广泛使用的糖尿病药物Mounjaro和减肥治疗Zepbound的活性成分。
In June, the Chinese National Medical Products Administration approved Novo Nordisk A/S's Wegovy (semaglutide) for long-term weight management.
六月份，中国国家药品监督管理局批准了诺和诺德A / S的Wegovy（semaglutide）用于长期减重管理。
The approval comes at a crucial time, as the patent for semaglutide is set to expire in China in 2026.
申请的批准在一个关键时期到来，因为semaglutide在中国的专利将于2026年到期。
Novo Nordisk also plans to limit the initial sales of its obesity treatment, Wegovy, in China. China's National Health Commission survey revealed over half of its 1.4 billion population is overweight or obese.
诺和诺德还计划限制其肥胖疗法Wegovy在中国的初期销售。据中国国家卫生健康委员会调查，超过14亿人口中有一半以上超重或肥胖。
Price Action: LLY stock is up 1.19% at $859.01 during the premarket session at the last check on Friday.
价格走势：截至上周五，LLY股票在盘前交易中涨1.19％，为859.01美元。